Serious liver disease induced by infliximab
Infliximab, a chimeric monoclonal antibody that binds the tumor necrosis factor ? (TNF?), is used in the treatment of rheumatoid arthritis (RA) and Crohn’s disease (CD). Previous cases of significant secondary liver disease associated with infliximab treatment have been reported in patients with RA,...
Autores Principales: | Tobon,Gabriel J, Cañas,Carlos, Jaller,Juan-Jose, Restrepo, Juan-Carlos, Anaya, Juan-Manuel |
---|---|
Formato: | Artículo (Article) |
Lenguaje: | Inglés (English) |
Publicado: |
Springer Nature
2006
|
Materias: | |
Acceso en línea: | https://repository.urosario.edu.co/handle/10336/25955 https://doi.org/10.1007/s10067-005-0169-y |
Ejemplares similares
-
Tuberculosis in the era of anti-TNF-alpha therapy : Why does the risk still exist?
por: Torres-Castiblanco, John Leonardo, et al.
Publicado: (2018) -
Tuberculosis in patientes treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile?
por: Rojas-Villarraga A., et al.
Publicado: (2007) -
Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview
por: Rodríguez, Sandra, et al.
Publicado: (8/1/) -
TNF microsatellites polymorphism is associated with rheumatoid arthritis. Confirming evidence in northwestern Colombians
por: Gomez L.M., et al.
Publicado: (2007) -
Autoimmunity and tuberculosis. Opposite association with TNF polymorphism.
por: Anaya, Juan Manuel, et al.
Publicado: (2005)